Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

  • STATUS
    Recruiting
  • End date
    Nov 1, 2024
  • participants needed
    30
  • sponsor
    Aiping Shi
Updated on 28 October 2021
cyclophosphamide
measurable disease
doxorubicin
docetaxel
triple negative breast cancer
mammogram

Summary

The purpose of this study is to evaluate the efficacy and safety of Camrelizumab plus chemotherapy as neoadjuvant therapy and Camrelizumab as adjuvant therapy in participants who have triple negative breast cancer (TNBC).

Description

After a screening phase of approximately 28 days, each participant will receive neoadjuvant study treatment (camrelizumab + chemotherapy) for approximately 24 weeks (8 cycles). Each participant will then undergo definitive surgery 2-4 weeks after the last cycle of the neoadjuvant treatment. After definitive surgery, each participant will receive adjuvant study treatment (camrelizumab) for approximately 27 weeks (9 cycles). Following adjuvant study treatment, each participant will be monitored for safety, survival and disease recurrence.

The primary study hypothesis is that camrelizumab is superior to chemotherapy, in combination with chemotherapy, as measured by the rate of Pathological Complete Response (pCR), Event-free Survival (EFS) and Objective Overall Response Rate (ORR) in participants with TNBC.

Details
Condition Triple Negative Breast Cancer, Breast Cancer
Treatment cyclophosphamide, docetaxel, doxorubicin, Camrelizumab
Clinical Study IdentifierNCT05088057
SponsorAiping Shi
Last Modified on28 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

18-70 Years, female
Histologically documented Triple Negative Breast Cancer (TNBC) patients
The subtypes of TNBC patients should include basal cell-like subtypes (BL1, BL2), Luminal androgenic type (LAR), and other types, such as mesenchymal type (M), mesenchymal stem cell type (MSL) and immunomodulatory type (IM)
Previously untreated non-metastatic (M0) TNBC, the primary tumor (T) and regional lymph node (N) combined staging determined by the investigator based on radiological and/or clinical evaluation. Stage at presentation: T1c, N1-N2; T2, N0-N2; T3, N0-N2
Promising radical surgical treatment
At least one measurable lesion according to RECIST 1.1
Life expectancy is not less than 3 months
ECOG: 01
Adequate function of major organs meets the following requirements
Neutrophils 1.510^9/L Hemoglobin 90g/L Platelets 10010^9/L Total bilirubin 1.5
the upper limit of normal (ULN) ALT and AST 2.5 ULN Serum creatinine 1.5 ULN
Endogenous creatinine clearance 50mL/min
\. Left ventricular ejection fraction (LVEF) 50% or limit of normal (LLN)
was evaluated by echocardiography (ECHO) or Multigated Acquisition (MUGA)
\. Women with childbearing potential who are must agree to take effective
contraceptive measures during the study period and 120 days after the last
administration of the study drug, and must have a negative serum pregnancy
test result within 7 days prior to initiation of study drug
\. The patient voluntarily joined the study, signed an informed consent
form, had good compliance, and cooperated with follow-up

Exclusion Criteria

Has participated in an interventional clinical study with an investigational compound within 4 weeks prior to initiation of study treatment
Prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies
Has a history of invasive malignancy 5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Active or history of autoimmune disease or immune deficiency diseases except history of autoimmune-related hypothyroidism, controlled Type 1 diabetes mellitus
Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases, including pulmonary fibrosis, acute lung disease, etc
Administration of a live attenuated vaccine within 30 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study
Has active infection (CTCAE2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment
Has a history of serious cardiovascular disease, including myocardial infarction, acute coronary syndrome or coronary angioplasty/stent implantation/bypass grafting history in the past 6 months, and have level II-IV congestion Heart failure (CHF), or III NYHA and IV CHF history
Prior allogeneic stem cell or solid organ transplantation
History of neurological or psychiatric disorders, including schizophrenia, severe depressive disorder, bipolar disorder, etc
Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
History of severe hypersensitivity reactions to other monoclonal antibodies, or intravenous infusion, or Doxorubicin, or cyclophosphamide, or docetaxel
Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial
Any other situation evaluated by researchers
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note